TY - JOUR
T1 - Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder
AU - Toren, Paz
AU - Rehavi, Moshe
AU - Luski, Anat
AU - Roz, Netta
AU - Laor, Nathaniel
AU - Lask, Michal
AU - Weizman, Abraham
PY - 2005/3
Y1 - 2005/3
N2 - The aim of the present study was to assess vesicular monoamine transporter (VMAT2) density in attention deficit/hyperactivity disorder (ADHD), a disorder involving monoaminergic dysregulation. It was hypothesized that the hypoactivity of monoaminergic neurotransmission related to ADHD could be associated with an under-expression of VMAT2. We assessed high affinity [3H] dihydrotetrabenazine [TBZOH] binding to platelet VMAT2 in untreated male ADHD children and adolescents (n=11) as compared to age-matched controls (n=14), as well as the correlation between VMAT2 density and the severity of ADHD symptoms as measured by the clinician-administered DSM-IV ADHD Scale (DAS) and the parent-administered Abbreviated Conners' Rating Scale (ACPRS). The [ 3H]TBZOH binding capacity (Bmax) was significantly lower (17%) in the ADHD group as compared to the controls. There was no difference between the two groups in the affinity (Kd value) of [3H]TBZOH to its binding site. An inverse correlation was found between the ADHD symptom scales and the Bmax values. It remains unclear whether the under-expression of platelet VMAT2 in ADHD children is reflective of a parallel change in the brain, and whether it is primary or an epiphenomenon of ADHD.
AB - The aim of the present study was to assess vesicular monoamine transporter (VMAT2) density in attention deficit/hyperactivity disorder (ADHD), a disorder involving monoaminergic dysregulation. It was hypothesized that the hypoactivity of monoaminergic neurotransmission related to ADHD could be associated with an under-expression of VMAT2. We assessed high affinity [3H] dihydrotetrabenazine [TBZOH] binding to platelet VMAT2 in untreated male ADHD children and adolescents (n=11) as compared to age-matched controls (n=14), as well as the correlation between VMAT2 density and the severity of ADHD symptoms as measured by the clinician-administered DSM-IV ADHD Scale (DAS) and the parent-administered Abbreviated Conners' Rating Scale (ACPRS). The [ 3H]TBZOH binding capacity (Bmax) was significantly lower (17%) in the ADHD group as compared to the controls. There was no difference between the two groups in the affinity (Kd value) of [3H]TBZOH to its binding site. An inverse correlation was found between the ADHD symptom scales and the Bmax values. It remains unclear whether the under-expression of platelet VMAT2 in ADHD children is reflective of a parallel change in the brain, and whether it is primary or an epiphenomenon of ADHD.
KW - Attention deficit/hyperactivity disorder
KW - Monoaminergic dysregulation
KW - Platelet vesicular monoamine transporter density
UR - http://www.scopus.com/inward/record.url?scp=13244295460&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2004.07.002
DO - 10.1016/j.euroneuro.2004.07.002
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15695060
AN - SCOPUS:13244295460
SN - 0924-977X
VL - 15
SP - 159
EP - 162
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 2
ER -